[go: up one dir, main page]

WO2019040106A3 - Compounds, salts thereof and their use in the treatment of diseases - Google Patents

Compounds, salts thereof and their use in the treatment of diseases Download PDF

Info

Publication number
WO2019040106A3
WO2019040106A3 PCT/US2018/000353 US2018000353W WO2019040106A3 WO 2019040106 A3 WO2019040106 A3 WO 2019040106A3 US 2018000353 W US2018000353 W US 2018000353W WO 2019040106 A3 WO2019040106 A3 WO 2019040106A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
compounds
salts
treatment
useful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2018/000353
Other languages
French (fr)
Other versions
WO2019040106A2 (en
Inventor
Ethan S. Burstein
Roger Olsson
Karl Erik Jansson
Niklas Patrik SKÖLD
Larisa Yudina WAHLSTRÖM
Henrik Von Wachenfeldt
Magnus Gustav Wilhelm BERGNER
Klaus DREISCH
Kyrylo POPOV
Oleksnadr KOVALENKO
Per Tomas Klingstedt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acadia Pharmaceuticals Inc
Original Assignee
Acadia Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acadia Pharmaceuticals Inc filed Critical Acadia Pharmaceuticals Inc
Publication of WO2019040106A2 publication Critical patent/WO2019040106A2/en
Publication of WO2019040106A3 publication Critical patent/WO2019040106A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/12—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/06—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present disclosure relates to compounds according to Formulae disclosed herein, useful for treating diseases.
PCT/US2018/000353 2017-08-21 2018-08-20 Compounds, salts thereof and methods for treatment of diseases Ceased WO2019040106A2 (en)

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US201762548309P 2017-08-21 2017-08-21
US201762548316P 2017-08-21 2017-08-21
US201762548314P 2017-08-21 2017-08-21
US201762548311P 2017-08-21 2017-08-21
US201762548305P 2017-08-21 2017-08-21
US201762548312P 2017-08-21 2017-08-21
US201762548304P 2017-08-21 2017-08-21
US62/548,314 2017-08-21
US62/548,316 2017-08-21
US62/548,312 2017-08-21
US62/548,309 2017-08-21
US62/548,311 2017-08-21
US62/548,305 2017-08-21
US62/548,304 2017-08-21

Publications (2)

Publication Number Publication Date
WO2019040106A2 WO2019040106A2 (en) 2019-02-28
WO2019040106A3 true WO2019040106A3 (en) 2019-04-18

Family

ID=65439592

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/000353 Ceased WO2019040106A2 (en) 2017-08-21 2018-08-20 Compounds, salts thereof and methods for treatment of diseases

Country Status (1)

Country Link
WO (1) WO2019040106A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021147818A1 (en) * 2020-01-21 2021-07-29 瀚远医药有限公司 5-ht2a receptor antagonist and application thereof in treating central nervous system diseases
CN115677723B (en) * 2020-01-21 2024-06-04 瀚远医药有限公司 5-HT2A receptor antagonists and their use for treating central nervous system disorders
CN113214231B (en) * 2020-01-21 2022-04-08 瀚远医药有限公司 5HT2A receptor antagonists and their medical uses
CN113549006B (en) * 2020-04-26 2023-07-21 江苏恩华药业股份有限公司 Amide derivative and application thereof
WO2022017440A1 (en) * 2020-07-22 2022-01-27 山东绿叶制药有限公司 5-ht2a receptor inhibitor or inverse agonist, preparation method therefor, and application thereof
CN113004207B (en) * 2021-03-05 2023-10-17 中国医科大学 PLK4 small molecule inhibitor compounds and their applications
PE20231987A1 (en) * 2021-03-10 2023-12-12 Jnana Therapeutics Inc SMALL MOLECULE INHIBITORS OF MAMMAL SLC6A19 FUNCTION
JP2025525188A (en) * 2022-08-03 2025-08-01 緑叶嘉奥制薬石家庄有限公司 5-HT2A RECEPTOR INVERSE AGONISTS, PREPARATION METHODS AND USE THEREOF - Patent application
WO2024059205A1 (en) * 2022-09-14 2024-03-21 Jnana Therapeutics, Inc.. Treating pku with spiro-substituted and other piperidine inhibitors of slc6a19 function
WO2024259100A2 (en) * 2023-06-14 2024-12-19 Jnana Therapeutics Inc. Piperidine inhibitor of slc6a19 function
WO2025061176A1 (en) * 2023-09-20 2025-03-27 上海科技大学 Cycloalkane-substituted amine derivative, preparation method therefor and use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1965805A1 (en) * 2005-11-25 2008-09-10 Proskelia SAS Urea derivatives useful as calcium receptor modulators
US20080280886A1 (en) * 2007-05-08 2008-11-13 Auspex Pharmaceuticals, Inc. Substituted ureas
WO2017015272A1 (en) * 2015-07-20 2017-01-26 Acadia Pharmaceuticals Inc. Methods for preparing n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form c

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1965805A1 (en) * 2005-11-25 2008-09-10 Proskelia SAS Urea derivatives useful as calcium receptor modulators
US20080280886A1 (en) * 2007-05-08 2008-11-13 Auspex Pharmaceuticals, Inc. Substituted ureas
WO2017015272A1 (en) * 2015-07-20 2017-01-26 Acadia Pharmaceuticals Inc. Methods for preparing n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form c

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NUTT, D. ET AL.: "Inverse agonists - What do they mean for psychiatry?", EUROPEAN NEUROPSYCHOPHARMACOLOGY, vol. 27, January 2017 (2017-01-01), pages 87 - 90, XP029884877, DOI: 10.1016/j.euroneuro.2016.11.013 *

Also Published As

Publication number Publication date
WO2019040106A2 (en) 2019-02-28

Similar Documents

Publication Publication Date Title
WO2019040106A3 (en) Compounds, salts thereof and their use in the treatment of diseases
ZA202001717B (en) Compounds, salts thereof and methods for treatment of diseases
WO2018112365A3 (en) Methods of treating colorectal cancer and melanoma using parabacteroides goldsteinii
WO2015073587A3 (en) Synthetic membrane-receiver complexes
EP4497474A3 (en) Methods of treating rheumatic diseases using trimetazidine-based compounds
WO2016037157A3 (en) Targeting capn9/capns2 activity as a therapeutic strategy for the treatment of myofibroblast differentiation and associated pathologies
WO2016118951A3 (en) Heterocyclic itk inhibitors for treating inflammation and cancer
HK1246286A1 (en) Lrrk2 inhibitors and methods of making and using the same
WO2015148863A3 (en) Crispr/cas-related methods and compositions for treating sickle cell disease
EP4282479A3 (en) Use of pridopidine to treat depression or anxiety
SG10201803862UA (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
WO2016172496A8 (en) Lsd1 inhibitors and uses thereof
WO2015066302A3 (en) Compositions, methods of use, and methods of treatment
WO2016055797A3 (en) Valproic acid for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation
EA033446B1 (en) Heterocyclic compound for treating macular degeneration and/or stargardt&#39;s disease
WO2015197193A3 (en) New use for jnk inhibitor molecules for treatment of various diseases
WO2016046156A8 (en) Substituted oxopyridine derivatives
WO2016004404A3 (en) Gls1 inhibitors for treating disease
WO2016004413A3 (en) Gls1 inhibitors for treating disease
EP4574832A3 (en) Dantrolene prodrugs and methods of their use
WO2015106215A3 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
EP4272832A3 (en) Antimicrobial compounds, compositions, and uses thereof
WO2015075062A3 (en) Method of treating hair
WO2019040105A3 (en) Compounds, salts thereof and their use in the treatment of diseases
WO2018211324A8 (en) Prodrugs for the treatment of disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18783159

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18783159

Country of ref document: EP

Kind code of ref document: A2